MSH2 and cancer: The heterozygous deletion of the entire EPCAM gene reported in patient U004 (Table S2) and also previously reported in an individual with Lynch syndrome associated cancer [37], was reported of unknown significance on cancer risk because, it is known that deletions of 3′ region of EPCAM gene are associated with silencing of MSH2 gene through the transcriptional read-through [38].